LBP-CD155 Liposome Nanovaccine Efficiently Resist Colorectal Cancer and Enhance ICB Therapy.

Statistical analysis was performed using a Student’s t -test, and the differences between test and control groups were judged to be significant at 0.01 < *P < 0.05 and extremely significant at **P < 0.01, ***P < 0.001 and ****P < 0.0001.

also in 7,787 other papers